Health Care · Pharmaceutical Preparations · Nasdaq · CIK 906709 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $70.68Day −0.13%Mkt cap $2.4B1Y +208.5%Off 52W high −35.2%Vol (1Y) 90.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,293 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest20.2% of sh out |
| Days to cover7.0d |
| 13F net flow (QoQ)+23.10% |
| Top-10 13F concentration53.1% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$55.6M |
| Earnings (TTM)-$158.1M |
| ROE−217.9% |
| Net margin−297.1% |
| ROIC−242.7% |
| Sales growth 3Y−15.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+67.2% |
| 1Y+208.5% |
| 3Y+783.8% |
| 5Y−70.5% |
| 10Y−72.6% |
| Since incept. (ann.)−6.3% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)90.5% |
| Ann. volatility (3Y)140.1% |
| Sharpe (1Y)1.63 |
| Sharpe (3Y)1.02 |
| Max drawdown (1Y)−46.5% |
| Max drawdown (3Y)−73.2% |
| Beta (3Y vs SPY)1.21 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 4.3M | $310M | 12.74% | +4155.1% |
| BVF INC/IL | 2.6M | $184M | 7.58% | +64.1% |
| Two Seas Capital LP | 2.0M | $141M | 5.80% | +162.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $86M | 3.54% | new |
| TWO SIGMA INVESTMENTS, LP | 930,741 | $67M | 2.75% | +96.8% |
| Prosight Management, LP | 735,000 | $53M | 2.18% | +32.5% |
| BlackRock, Inc. | 692,650 | $50M | 2.05% | +7.3% |
| MORGAN STANLEY | 659,387 | $47M | 1.95% | +16.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$1.82 | — | $10.9M | +3.8% |
| 2025-12-31 | 2026-03-12 | — | — | $21.8M | −25.3% |
| 2025-09-30 | 2025-11-06 | −$1.87 | — | $11.8M | −51.1% |
| 2025-06-30 | 2025-08-07 | −$2.95 | — | $11.2M | −52.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Non Cash Royalty Revenue Related To Sale Of Future Royalties 50% · Non Cash Royalties 50% · License Collaboration And Other Revenue 0%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
